These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. [Tyrosine kinases as targets of cancer therapy: from disbelief to Lazarus responses]. Joensuu H Duodecim; 2012; 128(21):2261-8. PubMed ID: 23210289 [TBL] [Abstract][Full Text] [Related]
9. Assessing the potential role of next generation tyrosine kinase inhibitors in the treatment of cancers with acquired kinase domain mutations. Thirumal Raj A; Patil S; Ranadheer R; Chandini R Oral Oncol; 2017 Oct; 73():172. PubMed ID: 28923250 [No Abstract] [Full Text] [Related]
10. Tyrosine kinases as targets for cancer therapy. Krause DS; Van Etten RA N Engl J Med; 2005 Jul; 353(2):172-87. PubMed ID: 16014887 [No Abstract] [Full Text] [Related]
11. The era of targeted therapies: increasing role for novel oncologic drugs in dermatology. Montella L; Palmieri G; Lacouture M Arch Dermatol; 2007 Jun; 143(6):788-9. PubMed ID: 17576948 [No Abstract] [Full Text] [Related]
12. Tyrosine kinases as targets in cancer therapy - successes and failures. Traxler P Expert Opin Ther Targets; 2003 Apr; 7(2):215-34. PubMed ID: 12667099 [TBL] [Abstract][Full Text] [Related]
13. Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Engelman JA; Settleman J Curr Opin Genet Dev; 2008 Feb; 18(1):73-9. PubMed ID: 18325754 [TBL] [Abstract][Full Text] [Related]
14. Influence of Prior Tyrosine Kinase Inhibitor on Survival for Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab or Cabozantinib: Data from a Literature-based Meta-analysis. Roviello G; Generali D Eur Urol; 2017 Dec; 72(6):1027-1028. PubMed ID: 28760645 [No Abstract] [Full Text] [Related]
15. Chronic myelogenous leukemia (CML): resistance to tyrosine kinase inhibitors. Hochhaus A Ann Oncol; 2006 Sep; 17 Suppl 10():x274-9. PubMed ID: 17018738 [No Abstract] [Full Text] [Related]
17. EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences. Dassonville O; Bozec A; Fischel JL; Milano G Crit Rev Oncol Hematol; 2007 Apr; 62(1):53-61. PubMed ID: 17324578 [TBL] [Abstract][Full Text] [Related]
18. Tyrosine kinases as molecular targets to inhibit cancer progression and metastasis. Cepero V; Sierra JR; Giordano S Curr Pharm Des; 2010; 16(12):1396-409. PubMed ID: 20166985 [TBL] [Abstract][Full Text] [Related]
19. Best Use of the Tyrosine Kinase Inhibitors in Progressive Differentiated Thyroid Cancer: Discussion. Tuttle RM; Brose MS Clin Adv Hematol Oncol; 2016 May; 14(5 Suppl 9):12-3. PubMed ID: 27168343 [No Abstract] [Full Text] [Related]
20. Current topics and the clinical effects of target-based antineoplastic agents. Maehara Y; Egashira A; Kakeji Y Int J Clin Oncol; 2006 Jun; 11(3):164-6. PubMed ID: 16850121 [No Abstract] [Full Text] [Related] [Next] [New Search]